Eurocine Vaccines AB
7 Jun - 21 Jun 2021Rights issue
Eurocine Vaccines develops vaccines for human and veterinary use. The company identifies, evaluates, selects and agrees on vaccine antigen for further development within its own vaccine portfolio based on a balance of several factors such as medical need, market potential, patent protection and technical feasibility. The vaccines are developed based on the company’s extensive knowledge and experience in the vaccine area and the technology platform Endocine ™.
Eurocine Vaccines are listed on the Spotlight Stock Market. The planned capitalization is carried out in order to finance the majority of the preparatory activities prior to the start of the first clinical study with the company’s vaccine candidate against chlamydia. In addition, the capitalization will finance business development, partly with the aim of preparing potential partners for the chlamydia vaccine candidate and partly to identify and evaluate additional vaccine candidates.
The offer in summary
Record date: 3 June 2021
Terms: Anyone who was a shareholder in the Company on the record date of 3 June 2021 has a preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share entails obtaining one (1) unit right. The last day for trading including preferential rights was 1 June 2021. The first day for trading without preferential rights was 2 June 2021. Two (2) unit rights entitle to subscribe for one (1) unit. Each unit consists of two (2) newly issued shares and one (1) free warrant of series TO 4. One (1) warrant of series TO 4 entitles the holder to subscribe for one (1) newly issued share in the Company.
Subscription period: 7 June - 21 June 2021
Subscription price: SEK 8.00 per unit
Trading in unit rights : 7 June - 16 June 2021.
Marketplace: Spotlight Stock Market
The newly issued warrants of series TO 4 are planned to be traded on Spotlight Stock Market as soon as possible after the Swedish Companies Registration Office has registered the rights issue. Each warrant of series TO 4 entitles to subscribe for one (1) new share in Eurocine Vaccines. The subscription price shall amount to seventy (70) percent of the average volume-weighted price for Eurocine Vaccine’s share according to Spotlight Stock Market’s official price statistics during the period of 10 trading days ending two (2) banking days before the exercise period begins. The subscription price shall not exceed SEK 5.00 per new share and shall not be less than the share’s quota value. The subscription price must be rounded to the nearest whole number of öre. Subscription of shares with the support of warrants of series TO 4 shall take place during the period 14 – 28 March 2022.